MedTrace Logo

Losmapimod in Chronic Obstructive Pulmonary Disease Patients Stratified by Fibrinogen.

NCT01541852 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2015-03-17

No results posted yet for this study

Summary

The main purpose of this study is to determine the effect of Losmapimod on blood vessels in patients with Chronic Obstructive Pulmonary Disease (COPD). Although COPD is a lung disease, it is also associated with an increased risk of cardiovascular disease (e.g. heart attacks and stroke). The investigators believe that this is a result of inflammation within the body, which damages the lining (endothelium) and walls of blood vessels. These changes can promote the development of fatty deposits within the walls of arteries (atherosclerosis) which can rupture and block arteries causing damage.

Conditions

Interventions

DRUG

Losmapimod

One tablet of Losmapimod 7.5mg twice daily

DRUG

Placebo

One tablet twice daily

Sponsors & Collaborators

  • Technology Strategy Board, United Kingdom

    collaborator OTHER

  • GlaxoSmithKline

    collaborator INDUSTRY

  • Royal Brompton & Harefield NHS Foundation Trust

    collaborator OTHER

  • University of Cambridge

    collaborator OTHER

  • Cambridge University Hospitals NHS Foundation Trust

    lead OTHER

Principal Investigators

  • Joseph Cheriyan, MD · Cambridge University Hospitals

  • Michael Polkey, MD · Royal Brompton & Harefield Foundation NHS Trust

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-06-30
Primary Completion
2014-02-28
Completion
2014-02-28

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01541852 on ClinicalTrials.gov